RYTM FY 2022 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$24M+649.5% YoY

Gross Profit

$22M91.0% margin

Operating Income

-$179M-757.9% margin

Net Income

-$181M-766.2% margin

EPS (Diluted)

$-3.51

Cash Flow

Operating Cash Flow

-$173M

Free Cash Flow

-$178M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$382M

Total Liabilities

$118M

Stockholders' Equity

$264M

Cash & Equivalents

$128M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$24M	$3M	+649.5%
Gross Profit	$22M	$3M	+741.7%
Operating Income	-$179M	-$170M	-5.3%
Net Income	-$181M	-$70M	-160.2%